Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 32

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 32
---
 prospects and the likelihood of success or failure     
 of its business.                                                                                                                       |

Risks Related to Doing Business in Hong Kong

| ● | Risks relating to legal and regulatory risks associated with our operations in Hong Kong.                                                                                                                                                                                                                                                                                                                                |
| ● | If we become directly subject to the recent scrutiny, criticism and negative publicity involving U.S.-listed Chinese companies, we may have to expend significant resources to investigate and resolve the matter which could harm our business operations, stock price and reputation and could result in a loss of your investment in our stock, especially if such matter cannot be addressed and resolved favorably. |
| ● | The recent joint statement by the SEC, proposed rule changes submitted by Nasdaq, and an act passed by the U.S. Senate and the U.S. House of Representatives, all call for additional and more stringent criteria to be applied to emerging market companies. These developments could add uncertainties to our offering, business operations, share price and reputation.                                               |
| ● | Our business, financial condition and results of operations, and/or the value of our Class A Ordinary Shares or our ability to offer or continue to offer securities to investors may be materially and adversely affected to the extent the laws and regulations of the PRC become applicable to a company such as us.                                                                                                  |

<div align='center'>10</div>

| ● | The uncertainties with respect to the Chinese legal system, including uncertainties regarding the enforcement of laws, and sudden or unexpected changes in laws and regulations in China with little advance notice could adversely affect us and limit the legal protections available to you and us. |

Risks Related to the Preclinical and Clinical Development of Our Drug Candidates

| ● | Risks                                       
 relating to not generate sufficient revenue |

| ● | Risks                                                      
 relating to uncertainty in preclinical development process |

| ● | Risks                                                   
 relating to fail to identify additional drug candidates |

| ● | Risks                                                      
 relating to conduct clinical trials in or outside the U.S. |

Risks Related to Obtaining Regulatory Approval for Our Drug Candidates

| ● | Risks                                                   
 relating to fail or delay to obtain regulatory approval |

| ● | Risks                                 
 relating to undesirable adverse event |

| ● | Risks                                                                            
 relating to fail to complete the 505(b)(2) pathway for the pediatric formulation |

| ● | Risks                                                                                                                          
 relating to our third-party suppliers fail to comply with the FDA’s good manufacturing practice regulations or fail to respond 
 to an FDA Form 483 or subsequent Warning Letter